News Lexaria Bioscience Corp.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.2 ^USD	-1.79%		-5.98%	+76.00%

Apr. 16	Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	MT
Apr. 16	Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	CI

Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	Apr. 16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16	CI
Lexaria Bioscience : Corporate Highlight Sheet	Apr. 11	PU
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02	CI
Lexaria Awarded New Patents	Apr. 02	AQ
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K	Mar. 21	PU
Lexaria to Present at The LD Micro Invitational XIV	Mar. 21	NE
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	Mar. 14	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	Mar. 14	AQ
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	Mar. 14	CI
Lexaria Bioscience : Corporate Highlight Sheet	Mar. 08	PU
Lexaria Awards Contract For Next GLP-1 Human Pilot Study	Mar. 07	AQ
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05	MT
Sector Update: Health Care	Mar. 05	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	Mar. 05	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	Mar. 05	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1	Mar. 05	AQ
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04	CI

No results for this search